Crystals of aromatic ring derivatives and their preparation and use
Calcium salts of specific crystal forms of compounds address the non-selectivity and side effects of existing S1P1 receptor agonists, providing improved therapeutic options for autoimmune diseases.
Patent Information
- Application Number
- JP2024535944
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-17
- Filing Date
- 2022-12-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-12-16
AI Technical Summary
Existing S1P1 receptor agonists, such as FTY720, are non-selective and cause significant side effects like bradycardia, limiting their therapeutic use in immune diseases.
Development of calcium salts of specific crystal forms of compounds represented by formula (I), characterized by distinct powder X-ray diffraction patterns, to act as highly selective S1P1 agonists with reduced side effects.
The calcium salts of these crystal forms provide enhanced selectivity and efficacy in treating autoimmune diseases with minimized side effects, offering a broader therapeutic range.
Smart Images

Figure 2024544717000001_ABST
Abstract
Description
[Technical field]
[0001] This application claims priority to: CN202111555458.X, application date is December 17, 2021.
[0002] The present invention relates to crystal forms, salt forms, pharmaceutical compositions and their use as S1P1 agonists of compounds of formula (I). [Background technology]
[0003] Sphingosine-1-phosphate (S1P) is an amphipathic biological signaling molecule belonging to the lysophospholipid (LP) family. S1P can activate complex downstream signals by acting on five G protein-coupled receptor subtypes, the sphingosine-1-phosphate receptors (S1PR1-5), thereby regulating important physiological and biochemical functions. S1P binds to various S1P receptors to regulate various physiological functions, and plays an important role in maintaining the body's health and in the development of diseases.
[0004] S1P1 receptor agonists disrupt lymphocyte trafficking, resulting in the sequestering of lymphocytes to lymph nodes and other secondary lymphoid tissues. This reduces peripheral circulating lymphocytes, and the clinical value of lymphocyte sequestration is to exclude lymphocytes from the sphere of inflammatory and / or autoimmune responses in surrounding tissues. This lymphocyte sequestration (e.g., in lymph nodes) is believed to be the result of the simultaneous action of agonist-driven functional antagonism of S1P1 receptors on T cells (thus reducing the ability of S1P to recruit T cell efflux from lymph nodes) and sustained agonism of S1P1 receptors on lymph node endothelium (thus improving barrier function against lymphocyte migration). Thus, S1P1 receptor agonists can be used as immune inhibitors to treat various autoimmune diseases, since they reduce the body's autoimmune capabilities by preventing lymphocyte trafficking.
[0005] Among them, the S1P1 agonist Fingolimod (FTY720) has been approved by the FDA as a treatment for relapsing multiple sclerosis (MS), opening up a new therapeutic field in the treatment of immune diseases. Although FTY720 has clinical efficacy, it is a non-selective S1P receptor agonist, and when FTY720 binds to S1P3 in vivo, it often causes a series of important side effects such as bradycardia, which greatly limits its scope of use in the treatment of immune diseases. Therefore, the discovery of second-generation highly selective S1P1 agonists that can be used as treatments for immune diseases with higher efficacy, fewer side effects, and a wider range of use has become one of the hotspots of pharmaceutical research.
[0006] The application, application number PCT / CN2019 / 123485 (filed December 6, 2019), provides an S1P1 agonist having the following structure: [ka] Summary of the Invention
[0007] The present invention provides a calcium salt of a compound of formula (I). [ka]
[0008] In some embodiments of the present invention, the calcium salt is [ka] It is.
[0009] The present invention further provides a G-type crystal of the calcium salt of the compound represented by formula (II), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 8.98±0.2°, 10.12±0.2°, 13.56±0.2°, 14.66±0.2°, 15.22±0.2°, and 18.48±0.2°.
[0010] In some embodiments of the present invention, the powder X-ray diffraction pattern of the G-type crystal has characteristic diffraction peaks at the following 2θ angles: 8.98±0.2°, 10.12±0.2°, 13.56±0.2°, 14.66±0.2°, 15.22±0.2°, 16.34±0.2°, 16.92±0.2°, 18.48±0.2°, 22.67±0.2°, and 23.06±0.2°.
[0011] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned G-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0012] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above G-type crystal is as shown in Table 7.
[0013] [Table 1]
[0014] In some embodiments of the present invention, the G-type crystal further comprises water and a solvent,
[0015] however, the solvent is selected from ethanol and isopropyl alcohol; The content of the solvent is 0.1% to 6.0%; The water content is 0.1 to 4.0%. In some embodiments of the present invention, the content of the solvent is 1.0% to 5.5%, and the content of water is 3.0% to 4.5%. In some embodiments of the present invention, the solvent is ethanol, the content of the ethanol is 1.0% to 5.5%, and the content of the water is 3.0% to 4.5%.
[0016] In some embodiments of the present invention, the content of the solvent is 1.64% to 4.77%, and the content of water is 3.09% to 4.37%.
[0017] In some embodiments of the present invention, the solvent is ethanol, the ethanol content is 1.64% to 4.77%, and the water content is 3.09% to 4.37%.
[0018] In some embodiments of the present invention, the solvent is ethanol, where the ethanol content is 4.77% and the water content is 3.09%.
[0019] In some embodiments of the present invention, the solvent is ethanol, where the ethanol content is 3.05% and the water content is 3.89%.
[0020] In some embodiments of the present invention, the solvent is ethanol, where the ethanol content is 1.97% and the water content is 4.37%.
[0021] In some embodiments of the present invention, the solvent is ethanol, where the ethanol content is 1.64% and the water content is 3.75%.
[0022] A characteristic diffraction peak as used herein is a peak selected from the observed diffraction pattern. When distinguishing between multiple crystalline solids, a peak that is visible in the crystalline solid but not in other crystalline solids relative to the size of the peak is a preferred characteristic peak for identifying the crystalline solid. Even one or two such characteristic peaks can characterize the crystalline solid.
[0023] In particular, the G-type crystal can be distinguished from other crystal forms (e.g., anhydrous) disclosed herein by the presence of characteristic diffraction peaks. In addition, if the measured charts are compared and the characteristic peaks match, it can be said that the powder X-ray diffraction patterns are substantially the same. The G-type crystal may change the hydration state of the solvent due to changes in the solvent and water content. Such G-type crystals with different solvent hydration contents have common characteristic peaks as shown in Figure 1, Figures 18 to 21.
[0024] In some embodiments of the present invention, the common characteristic peaks are at least three peaks selected from the following diffraction angles (2θ): 8.98±0.2°, 10.12±0.2°, 13.56±0.2°, 14.66±0.2°, 15.22±0.2°, 18.48±0.2°.
[0025] In some embodiments of the invention, the common characteristic peaks are at least three peaks selected from the following diffraction angles (2θ): 8.98±0.2°, 10.12±0.2°, 13.56±0.2°, 14.66±0.2°, 15.22±0.2°, 16.34±0.2°, 16.92±0.2°, 18.48±0.2°, 22.67±0.2°, 23.06±0.2°.
[0026] In the present invention, the content (%) represents a mass ratio, and the unit is g / g.
[0027] In a further aspect of the present invention, the present invention further provides a method for preparing G-type crystals. According to an embodiment of the present invention, the method includes dissolving the compound represented by formula (I) in sodium ethoxide solution, then stirring in the presence of calcium chloride, filtering, and drying under reduced pressure to obtain G-type crystals. This method is different from the general method of forming calcium salt crystals in the prior art, in that the method of the present invention adopts the condition of calcium chloride, not calcium hydroxide, and at the same time, requires drying before obtaining G-type crystals.
[0028] In some embodiments of the present invention, the above method includes heating a compound represented by formula (I) and absolute ethanol to 35-45°C, stirring for 5-30 minutes, adding a sodium ethoxide solution, stirring for 2-3 hours, adding a calcium chloride solution dropwise, stirring for 1-3 hours to react, cooling to 20-30°C, stirring for 4-6 hours, filtering, rinsing the cake with purified water, rinsing with ethanol, and drying the cake under reduced pressure at 25-35°C to obtain G-type crystals.
[0029] In some embodiments of the present invention, the mass ratio of sodium ethoxide to absolute ethanol in the sodium ethoxide solution is (0.01-0.05):(0.40-0.80).
[0030] In some embodiments of the present invention, the mass ratio of sodium ethoxide to absolute ethanol in the above sodium ethoxide solution is 0.035:0.631.
[0031] In some embodiments of the present invention, the mass ratio of calcium chloride to pure water in the calcium chloride solution is (0.01-0.08):(0.20-1.00).
[0032] In some embodiments of the present invention, the mass ratio of calcium chloride to pure water in the calcium chloride solution is 0.040:0.847.
[0033] The present invention relates to [ka] Further provided is a crystalline form A of the compound of formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 5.25±0.2°, 6.28±0.2°, 10.5±0.2°, 12.69±0.2°, 15.45±0.2°, and 16.02±0.2°.
[0034] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Type A crystal has characteristic diffraction peaks at the following 2θ angles: 5.25±0.2°, 6.28±0.2°, 10.5±0.2°, 12.69±0.2°, 15.45±0.2°, 16.02±0.2°, 16.60±0.2°, 20.66±0.2°, 21.39±0.2°, and 22.28±0.2°.
[0035] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Form A crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0036] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above-mentioned A-type crystal is as shown in Table 1 below.
[0037] [Table 2]
[0038] The present invention further provides a B-type crystal of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 6.96±0.2°, 11.71±0.2°, 15.55±0.2°, 17.35±0.2°, 20.62±0.2°, and 21.16±0.2°.
[0039] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned B-type crystals has characteristic diffraction peaks at the following 2θ angles: 6.96±0.2°, 10.80±0.2°, 11.71±0.2°, 13.39±0.2°, 15.55±0.2°, 17.35±0.2°, 18.45±0.2°, 20.62±0.2°, 21.16±0.2°, and 21.81±0.2°.
[0040] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned B-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0041] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above B-type crystals is as shown in Table 2.
[0042] [Table 3]
[0043] The present invention further provides a C-type crystal of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 12.69±0.2°, 14.38±0.2°, 16.23±0.2°, 17.40±0.2°, 18.61±0.2°, and 19.74±0.2°.
[0044] In some embodiments of the present invention, the powder X-ray diffraction pattern of the C-type crystal has characteristic diffraction peaks at the following 2θ angles: 12.69±0.2°, 14.38±0.2°, 16.23±0.2°, 17.40±0.2°, 18.61±0.2°, 19.74±0.2°, 20.46±0.2°, 20.94±0.2°, 21.75±0.2°, and 25.44±0.2°.
[0045] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned C-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0046] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above C-type crystal is as shown in Table 3.
[0047] [Table 4]
[0048] The present invention further provides a D-type crystal of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 9.33±0.2°, 13.94±0.2°, 18.82±0.2°, 22.76±0.2°, 24.24±0.2°, and 27.90±0.2°.
[0049] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Form D crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0050] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above D-type crystal is as shown in Table 4.
[0051] [Table 5]
[0052] The present invention further provides type E crystals of the compound represented by formula (I), which have a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 6.84±0.2°, 10.65±0.2°, 11.53±0.2°, 15.41±0.2°, 17.29±0.2°, and 20.65±0.2°.
[0053] In some embodiments of the present invention, the powder X-ray diffraction pattern of the E-type crystal has characteristic diffraction peaks at the following 2θ angles: 6.84±0.2°, 10.65±0.2°, 11.53±0.2°, 13.78±0.2°, 15.41±0.2°, 17.29±0.2°, 20.22±0.2°, 20.65±0.2°, 23.90±0.2°, and 25.26±0.2°.
[0054] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Form E crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0055] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above-mentioned E-form crystals is as shown in Table 5.
[0056] [Table 6]
[0057] The present invention further provides a diethylamine salt of the compound of formula (I).
[0058] The present invention further provides an F-type crystal of the diethylamine salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 10.36±0.2°, 10.96±0.2°, 12.01±0.2°, 13.05±0.2°, 16.66±0.2°, and 18.99±0.2°.
[0059] In some embodiments of the present invention, the powder X-ray diffraction pattern of the F-type crystal has characteristic diffraction peaks at the following 2θ angles: 10.36±0.2°, 10.96±0.2°, 12.01±0.2°, 13.05±0.2°, 16.66±0.2°, 18.99±0.2°, 20.42±0.2°, 20.98±0.2°, 22.11±0.2°, and 23.93±0.2°.
[0060] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned F-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0061] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above-mentioned F-type crystal is as shown in Table 6.
[0062] [Table 7]
[0063] The present invention further provides an H-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 7.32±0.2°, 9.57±0.2°, 11.83±0.2°, 12.76±0.2°, 13.48±0.2°, and 14.83±0.2°.
[0064] In some embodiments of the present invention, the powder X-ray diffraction pattern of the H-type crystals has characteristic diffraction peaks at the following 2θ angles: 7.32±0.2°, 9.57±0.2°, 11.83±0.2°, 12.76±0.2°, 13.48±0.2°, 14.83±0.2°, 16.64±0.2°, 17.69±0.2°, 18.91±0.2°, and 21.33±0.2°.
[0065] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned H-form crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0066] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above H-form crystals is as shown in Table 8.
[0067] [Table 8]
[0068] The present invention further provides Type I crystals of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 7.27±0.2°, 8.93±0.2°, 11.23±0.2°, 12.34±0.2°, 13.66±0.2°, and 16.06±0.2°.
[0069] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Form I crystal has characteristic diffraction peaks at the following 2θ angles: 7.27±0.2°, 8.93±0.2°, 11.23±0.2°, 12.34±0.2°, 13.66±0.2°, 16.06±0.2°, 17.97±0.2°, 20.82±0.2°, 23.42±0.2°, and 24.38±0.2°.
[0070] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above Form I crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0071] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above Form I crystal is as shown in Table 9.
[0072] [Table 9]
[0073] The present invention further provides a J-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 8.73±0.2°, 9.49±0.2°, 11.99±0.2°, 12.89±0.2°, 15.16±0.2°, and 19.58±0.2°.
[0074] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above J-type crystal has characteristic diffraction peaks at the following 2θ angles: 4.52±0.2°, 8.73±0.2°, 9.49±0.2°, 11.99±0.2°, 12.89±0.2°, 15.16±0.2°, 19.58±0.2°, 21.96±0.2°, 24.84±0.2°, and 26.66±0.2°.
[0075] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned J-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0076] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above J-type crystal is as shown in Table 10.
[0077] [Table 10]
[0078] The present invention further provides a K-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 8.57±0.2°, 9.32±0.2°, 11.06±0.2°, 12.65±0.2°, 14.08±0.2°, and 14.71±0.2°.
[0079] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned K-type crystal has characteristic diffraction peaks at the following 2θ angles: 7.66±0.2°, 8.57±0.2°, 9.32±0.2°, 11.06±0.2°, 12.65±0.2°, 14.08±0.2°, 14.71±0.2°, 15.08±0.2°, 15.79±0.2°, and 19.29±0.2°.
[0080] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Form K crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0081] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above-mentioned K-type crystals is as shown in Table 11 below.
[0082] [Table 11]
[0083] The present invention further provides an L-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 8.69±0.2°, 9.78±0.2°, 13.46±0.2°, 14.72±0.2°, 15.40±0.2°, and 15.98±0.2°.
[0084] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Form L crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0085] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above-mentioned Form L crystal is as shown in Table 12.
[0086] [Table 12]
[0087] The present invention further provides an M-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 8.09±0.2°, 10.87±0.2°, 13.62±0.2°, 14.55±0.2°, 15.77±0.2°, and 16.39±0.2°.
[0088] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned M-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0089] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above M-type crystals is as shown in Table 13.
[0090] [Table 13]
[0091] The present invention further provides an N-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 7.79±0.2°, 12.44±0.2°, 14.94±0.2°, 16.11±0.2°, 17.50±0.2°, and 20.98±0.2°.
[0092] In some embodiments of the present invention, the powder X-ray diffraction pattern of the N-type crystals described above has an X-ray powder diffraction pattern essentially as shown in FIG.
[0093] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above N-type crystal is as shown in Table 14.
[0094] [Table 14]
[0095] The present invention further provides an O-type crystal of the calcium salt of the compound represented by formula (I), which has a powder X-ray diffraction pattern having characteristic diffraction peaks at the following 2θ angles: 7.40±0.2°, 8.52±0.2°, 12.01±0.2°, 12.24±0.2°, 14.67±0.2°, and 16.86±0.2°.
[0096] In some embodiments of the present invention, the powder X-ray diffraction pattern of the O-type crystal has characteristic diffraction peaks at the following 2θ angles: 7.40±0.2°, 8.52±0.2°, 12.01±0.2°, 12.24±0.2°, 14.67±0.2°, 15.35±0.2°, 16.86±0.2°, 18.05±0.2°, 19.77±0.2°, and 22.02±0.2°.
[0097] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned O-type crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0098] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above O-type crystals is as shown in Table 15.
[0099] [Table 15]
[0100] The present invention further provides a P-type crystal of the calcium salt of the compound represented by formula (I), characterized in that the powder X-ray diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 11.49±0.2°, 13.38±0.2°, 14.04±0.2°, 16.28±0.2°, 16.78±0.2°, 20.22±0.2°, and 20.86±0.2°.
[0101] In some embodiments of the present invention, the powder X-ray diffraction pattern of the P-type crystal has characteristic diffraction peaks at the following 2θ angles: 11.49±0.2°, 13.38±0.2°, 14.04±0.2°, 16.28±0.2°, 16.78±0.2°, 18.81±0.2°, 20.22±0.2°, 20.86±0.2°, 23.16±0.2°, 24.66±0.2°, and 25.87±0.2°.
[0102] In some embodiments of the present invention, the powder X-ray diffraction pattern of the P-type crystals described above has an X-ray powder diffraction pattern essentially as shown in FIG.
[0103] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above P-type crystal is as shown in Table 16.
[0104] [Table 16]
[0105] The present invention further provides a strontium salt of the compound of formula (I).
[0106] In some embodiments of the present invention, the Q-type crystal of the strontium salt of the compound represented by formula (I) above is characterized in that its powder X-ray diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 5.01±0.2°, 8.96±0.2°, 10.08±0.2°, 13.54±0.2°, 14.84±0.2°, and 24.67±0.2°.
[0107] In some embodiments of the present invention, the powder X-ray diffraction pattern of the Q-type crystal has characteristic diffraction peaks at the following 2θ angles: 5.01±0.2°, 8.96±0.2°, 10.08±0.2°, 13.54±0.2°, 14.84±0.2°, 18.43±0.2°, 21.10±0.2°, 22.10±0.2°, 23.80±0.2°, and 24.67±0.2°.
[0108] In some embodiments of the present invention, the powder X-ray diffraction pattern of the above-mentioned Type Q crystals has an X-ray powder diffraction pattern essentially as shown in FIG.
[0109] In some embodiments of the present invention, the analytical data of the powder X-ray diffraction pattern of the above-mentioned Q-type crystal is as shown in Table 17.
[0110] [Table 17]
[0111] The present invention further provides a pharmaceutical composition comprising the A-type crystal, B-type crystal, C-type crystal, D-type crystal, E-type crystal, diethylamine salt, F-type crystal, calcium salt, G-type crystal, H-type crystal, I-type crystal, J-type crystal, K-type crystal, L-type crystal, M-type crystal, N-type crystal, O-type crystal, P-type crystal, strontium salt or Q-type crystal.
[0112] In some embodiments of the present invention, the pharmaceutical composition further comprises a pharma- ceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or a combination thereof.
[0113] The present invention further provides use of the A-type crystals, B-type crystals, C-type crystals, D-type crystals, E-type crystals, diethylamine salt, F-type crystals, calcium salt, G-type crystals, H-type crystals, I-type crystals, J-type crystals, K-type crystals, L-type crystals, M-type crystals, N-type crystals, O-type crystals, P-type crystals, strontium salt, Q-type crystals or pharmaceutical compositions in the preparation of a medicine for use in an S1P1 receptor-related disease.
[0114] In some embodiments of the present invention, the S1P1 receptor-associated disease is selected from ulcerative colitis, Crohn's disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, primary biliary cholangitis, atopic dermatitis, intracerebral hemorrhage, graft-versus-host disease, psoriasis, type I diabetes, acne, microbial infections or diseases, and viral infections and diseases.
[0115] Definitions and Explanations
[0116] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and published publications referenced herein are incorporated by reference in their entirety. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are described herein.
[0117] "Crystal" or "crystalline form" refers to a solid having a highly ordered chemical structure, including, but not limited to, single or multi-component crystals and / or crystalline polymorphs of a compound, solvates, hydrates, clathrates, eutectics, salts, solvates of salts, and hydrates of salts. Crystalline forms of a substance can be obtained by many methods known in the art. Such methods include, but are not limited to, melt crystallization, melt cooling, solvent crystallization, crystallization in confined spaces (e.g., in nanopores or capillaries), crystallization on surfaces or templates (e.g., on polymers), crystallization in the presence of additives such as co-crystallized antimolecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, reactive crystallization, antisolvent addition, grinding, and solvent drop grinding.
[0118] "Amorphous" or "amorphous form" refers to a substance formed when the particles (molecules, atoms, ions) of a substance are arranged in three-dimensional space without periodicity, and are characterized by a powder X-ray diffraction pattern without diffuse peaks. Amorphous is a special physical form of solid matter, whose locally ordered structural characteristics suggest that amorphous is intimately and inseparably related to crystalline matter. Amorphous forms of substances can be obtained by many methods known in the art. Such methods include, but are not limited to, quenching, antisolvent aggregation, ball milling, spray drying, freeze drying, wet granulation, and solid dispersion techniques.
[0119] "Solvent" refers to a substance (usually a liquid) capable of completely or partially dissolving another substance (usually a solid). Solvents used in the practice of the invention include, but are not limited to, water, acetic acid, acetone, acetonitrile, benzene, chloroform, carbon tetrachloride, dichloromethane, dimethylsulfoxide, 1,4-dioxane, ethanol, ethyl acetate, butanol, tert-butanol, N,N-dimethylacetamide, N,N-dimethylformamide, formamide, formic acid, heptane, hexane, isopropyl alcohol, methanol, methyl ethyl ketone, 1-methyl-2-pyrrolidone, mesitylene, nitromethane, polyethylene glycol, propanol, 2-propanone, pyridine, tetrahydrofuran, toluene, xylene, mixtures thereof, and the like.
[0120] "Antisolvent" refers to a fluid that promotes precipitation of a product (or product precursor) from a solvent. Antisolvents may include cold gases, or fluids that promote precipitation by chemical reaction, or fluids that reduce the solubility of the product in the solvent, which may be the same liquid as the solvent but at a different temperature, or a different liquid than the solvent.
[0121] "Solvate" refers to a solvent on the surface, in the crystal lattice, or on the surface and in the crystal lattice, where the solvent may be water, acetic acid, acetone, acetonitrile, benzene, chloroform, carbon tetrachloride, dichloromethane, dimethylsulfoxide, 1,4-dioxane, ethanol, ethyl acetate, butanol, tert-butanol, N,N-dimethylacetamide, N,N-dimethylformamide, formamide, formic acid, heptane, hexane, isopropyl alcohol, methanol, methyl ethyl ketone, methylpyrrolidone, mesitylene, nitromethane, polyethylene glycol, propanol, 2-propanone, pyridine, tetrahydrofuran, toluene, xylene, and mixtures thereof. An example of a solvate is a hydrate, where the solvent on the surface, in the crystal lattice, or on the surface and in the crystal lattice is water. The hydrate may or may not have a solvent other than water on the surface, in the crystal lattice, or on the surface and in the crystal lattice of the material.
[0122] Crystalline or amorphous can be identified by various technical methods such as X-ray powder diffraction (XRPD), infrared absorption spectroscopy (IR), melting point method, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), nuclear magnetic resonance, Raman spectroscopy, X-ray single crystal diffraction, solution calorimetry, scanning electron microscopy (SEM), quantitative analysis, solubility and dissolution rate.
[0123] X-ray powder diffraction (XRPD) can detect information such as crystal changes, crystallinity, and crystal structure state, and is a common method for identifying crystals. The peak positions of the XRPD pattern mainly depend on the structure of the crystal and are relatively insensitive to experimental details, while the relative peak heights depend on many factors related to the preparation of the sample and the geometry of the instrument. Thus, in some embodiments, the crystals of the present invention are characterized by XRPD patterns having specific peak positions substantially shown in the XRPD patterns provided in the drawings of the present invention. At the same time, the measurement of 2θ in the XRPD pattern may have experimental errors, and the measurement of 2θ in the XRPD pattern may vary slightly between different instruments and different samples, so the value of said 2θ cannot be considered absolute. Due to the state of the instrument used in the test of the present invention, the diffraction peaks have an error tolerance of ±0.2°.
[0124] Differential scanning calorimetry (DSC) is a technique that measures the energy difference between a sample and an inert reference material (usually α-Al2O3) as a function of temperature by continuously heating or cooling under program control. The height of the melting peak in the DSC curve depends on many factors related to the preparation of the sample and the geometry of the instrument, while the position of the peak is relatively insensitive to the experimental details. Thus, in some embodiments, the crystals described in the present invention are characterized by a DSC pattern having a characteristic peak position substantially as shown in the DSC pattern provided in the drawings of the present invention. At the same time, the peak position and peak value of the DSC endothermic peak cannot be considered absolute, since the DSC pattern may have experimental errors, and the peak positions and peak values of the DSC pattern may differ slightly between different instruments and different samples. There is a tolerance of error of ±3°C for the melting peak, depending on the condition of the instrument used in the test of the present invention.
[0125] Solids with the same chemical composition often form isomers or variants with different crystal structures under different thermodynamic conditions, a phenomenon called polymorphism. When temperature and pressure conditions change, variants can change into each other, a phenomenon called crystal transition. The change in crystals causes significant changes in the mechanical, electrical, magnetic, and other properties of the crystals. If the temperature of the crystal transition is within a measurable range, this transition process can be observed in a differential scanning calorimetry (DSC) pattern, and the DSC pattern is characterized by the simultaneous presence of two or more endothermic peaks, which are characteristic endothermic peaks of different crystals before and after the transition. The crystal or amorphous of the compound of the present invention may undergo crystal transition under appropriate conditions.
[0126] Thermogravimetric analysis (TGA) is a technique for measuring the mass change of a substance as a function of temperature under program control. It is suitable for investigating the reduction of solvent in a crystal and the sublimation and decomposition process of a sample, and can infer the presence of crystallized water or crystallization solvent in the crystal. The mass change represented by the TGA curve depends on many factors such as the sample preparation and the instrument, and the mass change detected by TGA varies slightly depending on the instrument and the sample. In some examples, the A-type crystal of the calcium salt described herein has a weight loss of about 5.1% at a temperature of about 150°C. The mass change has an error tolerance of ±0.3% depending on the condition of the instrument used in the test of the present invention.
[0127] In the context of the present invention, all 2θ values in X-ray powder diffraction patterns are expressed in degrees (°).
[0128] The term "essentially shown in the figure" refers to at least 50%, or at least 60%, or at least 70%, or at least 80%, or at least 90%, or at least 95%, or at least 99% of the peaks in the X-ray powder diffraction pattern or DSC pattern or TGA result are represented in the pattern.
[0129] When referring to data appearing in a pattern or graph, a "peak" refers to a feature recognizable by one of ordinary skill in the art that is not due to background noise.
[0130] In the context of the present invention, the terms "about" or "approximately", when used or not, mean within 10%, suitably within 5%, in particular within 1% of a given value or range. Alternatively, for those skilled in the art, the term "about" or "approximately" means within an acceptable standard error of the mean. Whenever a numerical value with a value of N is disclosed, a numerical value within N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, or N+ / -10% is expressly disclosed, where "+ / -" refers to plus or minus.
[0131] The term "comprises" is open-ended, i.e. includes the subject matter specified in the present invention, but does not exclude other aspects.
[0132] The salt forms or crystals or pharmaceutical compositions of the present invention can be used to prepare a medicament for use in treating an S1P1 receptor-associated disease, wherein the S1P1 receptor-associated disease is selected from Ulcerative colitis, Crohn's disease, Multiple sclerosis, Systemic lupus erythematosus, Lupus nephritis, Rheumatoid arthritis, Primary Biliary Cholangitis, Atopic Dermatitis, Intracerebral hemorrhage, Graft versus Host Disease, Psoriasis, Type I diabetes, Acne, microbial infections or diseases, and viral infections or diseases. [Brief description of the drawings]
[0133] [Figure 1] This is the powder X-ray diffraction (XRPD) pattern of the A-type crystal. [Diagram 2] This is the powder X-ray diffraction (XRPD) pattern of the B-type crystals. [Diagram 3] This is the powder X-ray diffraction (XRPD) pattern of the C-type crystals. [Figure 4] This is the powder X-ray diffraction (XRPD) pattern of the D-type crystal. [Diagram 5] This is the powder X-ray diffraction (XRPD) pattern of the E-form crystals. [Figure 6] This is the powder X-ray diffraction (XRPD) pattern of the F-type crystals. [Figure 7] This is the powder X-ray diffraction (XRPD) pattern of the G-type crystal. [Figure 8]This is the powder X-ray diffraction (XRPD) pattern of H-type crystals. [Figure 9] This is the powder X-ray diffraction (XRPD) pattern of the Form I crystal. [Figure 10] This is the powder X-ray diffraction (XRPD) pattern of the J-type crystal. [Figure 11] This is the powder X-ray diffraction (XRPD) pattern of the K-type crystal. [Figure 12] This is the powder X-ray diffraction (XRPD) pattern of the L-type crystal. [Figure 13] This is the powder X-ray diffraction (XRPD) pattern of M-type crystals. [Figure 14] This is the powder X-ray diffraction (XRPD) pattern of the N-type crystal. [Figure 15] This is the powder X-ray diffraction (XRPD) pattern of the O-type crystals. [Figure 16] This is a powder X-ray diffraction (XRPD) pattern of the P-type crystal. [Figure 17] This is the powder X-ray diffraction (XRPD) pattern of the Q-type crystals. [Figure 18] This is the powder X-ray diffraction (XRPD) pattern of the G-type crystal. [Figure 19] This is the powder X-ray diffraction (XRPD) pattern of the G-type crystal. [Figure 20] This is the powder X-ray diffraction (XRPD) pattern of the G-type crystal. [Figure 21] This is the powder X-ray diffraction (XRPD) pattern of the G-type crystal. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0134] The present invention will be described in detail below with reference to examples, which are not intended to limit the present invention in any way. The present invention has been described in detail herein, and specific embodiments thereof have been disclosed. It is apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present invention without departing from the spirit and scope of the present invention.
[0135] The powder X-ray diffraction analysis method used in this invention is carried out at room temperature using a Bruker D2 PHASER diffractometer (300W low power X-ray emitter). During the test, a silicon wafer is used to place the sample powder, and an X-ray Cu (Kα) tube is used, with an intensity ratio of Kα2 / Kα1 being 0.50 (1.54439 Å / 1.5406 Å). The instrument is set at 30 kV and 10 mA, with a step size of 0.02° (2θ), a scan time of 0.15 seconds per step, and a total of 1837 steps.
[0136] The differential scanning calorimetry (DSC) analysis method used in the present invention uses a TA Discovery DSC to collect differential scanning calorimetry data. The specific method is to weigh out a few milligrams of sample and place it in a Tzero aluminum tray, then seal it with the corresponding Tzero aluminum tray lid. Under a nitrogen gas atmosphere, the sealed sample is heated from room temperature to 300°C at a heating rate of 10°C / min.
[0137] The thermogravimetric analysis (TGA) method used in the present invention uses a TA Discovery TGA to collect thermogravimetric analysis data. In a specific method, a few milligrams of a sample is heated from room temperature to 350° C. at a heating rate of 10° C. / min under a nitrogen gas atmosphere.
[0138] The polarized light microscopy (PLM) analysis method used in the present invention uses an Olympus BX53M polarized light microscope to analyze the morphology of samples at room temperature.
[0139] The high performance liquid chromatography (HPLC) analysis method used in the present invention was used to test the purity and stability of the samples using an Agilent 1260, and the conditions used were as shown in Table 18 below.
[0140] [Table 18]
[0141] The hygroscopicity analysis method used in the present invention uses SMS ADVENTURE DVS to evaluate the hygroscopicity of a sample under a nitrogen gas atmosphere at 25° C. Approximately 30 mg of a sample is used for the test, and the test method is as follows:
[0142] Method 1 (for anhydrous crystals): 0%RH~95%RH, 10% RH increase in each step (90~95%RH is 5% RH increase), 95%RH~0%RH, 10% RH decrease in each step (5% RH decrease from 95~90%RH).
[0143] Method 2 (for water cosolvates): Ambient humidity ~95%RH, 10% RH increase for each step (90~95%RH 5% RH increase), 95%RH~0%RH, 10% RH decrease at each stage (5% RH decrease from 95%~90%RH), 0%RH~95%RH, with each step increasing RH by 10% (90~95%RH increases RH by 5%)
[0144] The analytical method for measuring the moisture content in the present invention is to use a Karl Fischer moisture titrator (Karl Fischer, KF) from Switzerland, Metrohm870 / 803, to collect the moisture content data of the sample. The measurement is carried out using the volumetric method, the titrant is Hydranal Composite-2 (Sigma-Aldrich, P / N:34806), the solvent is anhydrous methanol, and the stirring time is 30s. The specific operation is to weigh ~50mg of sample (with an accuracy of 0.001g), measure the moisture content of the sample with the above KF moisture titrator, measure twice in parallel, and take the average value.
[0145] Liquid nuclear magnetic resonance (1H NMR) of the present invention: Sample analysis is performed using a Bruker 400M nuclear magnetic resonance instrument, and DMSO-d6 is used as the solvent.
[0146] The present invention's solid-state nuclear magnetic (ssNMR): A Bruker 500MHz wide-bore solid-state nuclear magnetic resonance analyzer (400 MHz WB Solid-State Nuclear Magnetic Resonance Spectrometer) and a 4mm double-resonance magic-angle coil rotating probe are used to collect data. The cross-polarization / magic-angle rotation (CP / MAS) method is used, and the sideband suppression technique (TOSS) is embedded at the same time to avoid the influence of the rotating sideband, and the 13C fingerprint pattern of the sample is collected. The cross-polarization matching conditions are optimized using adamantane, and the chemical shift is corrected using the adamantane high-field signal (29.5 ppm). The magic angle velocity is 8kHz, 1H 90-degree pulse is 3.45us, and the decoupling method is TPPM. The specific test conditions are as follows:
[0147] 2# Test: Pulse delay 8s, contact time 2ms, cumulative 1500 times. 3# Test: Pulse delay 2s, contact time 2ms, cumulative 1500 times. 4# Test: Pulse delay 2s, contact time 0.2ms, cumulative 3100 times.
[0148] The abbreviations or English Japanese meanings of the solvents used in the present invention are as shown in Table 19 below:
[0149] [Table 19]
[0150] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, specific examples of the present invention will be described in order to enable those skilled in the art to better understand the present invention.
[0151] Example 1: Preparation of A-type crystals The compound represented by formula (I) was stirred in anisole / n-heptane (4:3, v / v) at room temperature to precipitate a solid, which was filtered and dried in vacuum at 45° C. for 36 hours to obtain type A crystals.
[0152] Example 2: Preparation of B-type crystals The compound represented by formula (I) (2.0 g) was dissolved in IPAC (10 mL), heated to 60° C., heptane (40 mL) was added dropwise, and cooled to 40° C. A large amount of solid began to precipitate, and heptane (10 mL) was added, stirred for 2 hours, filtered, and vacuum dried at 45° C. for 36 hours to obtain type B crystals.
[0153] Example 3: Preparation of D-type crystals The compound represented by formula (I) was stirred in MeOH / H2O (9:2, v / v) at room temperature to precipitate a solid, which was filtered and dried in vacuum at 45°C for 36 hours to obtain type D crystals.
[0154] Example 4: Preparation of C-type crystals The D-type crystals were heated to 137° C. to obtain C-type crystals.
[0155] Example 5: Preparation of E-type crystals The compound represented by formula (I) was stirred in CPME / heptane (2:3, v / v) at room temperature to precipitate a solid, which was filtered and dried in vacuum at 45° C. for 36 hours to obtain E-type crystals.
[0156] Example 6: Preparation of F-type crystals (including a salt formation step) The compound represented by formula (I) (0.4 g) was dissolved in EtOH (3.0 mL) at room temperature, stirred to dissolve, and then a solution of diethylamine in ethanol (diethylamine: 69.4 mg, ethanol: 0.8 mL) was slowly added. The mixture was stirred at room temperature for 19 hours to precipitate a solid, which was then filtered and vacuum dried at 30°C for 3 hours to obtain F-type crystals.
[0157] Example 7: G-type crystal [ka]
[0158] Method 1: Compound represented by formula (I) (0.2651 kg, 0.595 mol) and absolute ethanol (0.9488 kg) were added to a reaction vessel, heated to 35-45°C, and stirred for 5-30 minutes. Sodium ethoxide solution (sodium ethoxide: 0.035 Kg, 0.514 mol, absolute ethanol: 0.6310 kg) was added, stirred for 2-3 hours, calcium chloride solution (calcium chloride: 0.040 Kg, 0.357 mol, purified water: 0.847 Kg) was added dropwise, stirred for 1-3 hours to react, cooled to 20-30°C, stirred for 4-6 hours, filtered, and the cake was rinsed with purified water and then rinsed with ethanol. The cake was dried under reduced pressure at 25-35°C to obtain 0.2185 kg of G-type crystals of compound represented by formula (II), with a yield of 79.1%.
[0159] Method 2: 10.72 g of compound of formula (I) was weighed into a single-neck flask, EtOH (105 mL) was added, magnetic stirring for ~0.5 h, CHOna (1.64 g) was added, stirring at room temperature for 1.5 h, anhydrous CaCl (1.5 g) was dissolved in EtOH / HO (2:1, v / v, 45 mL), 1% seed crystal (G-type crystal) calcium chloride solution was added dropwise, stirring for 16 h, suspension was taken, XRPD of the sample was measured, which showed it to be D-type crystal, filtered, the cake was washed twice each with HO and EtOH, XRPD of the wet sample was measured, which showed it to be J-type crystal, dried under vacuum at 50 °C for 4 h, XRPD was measured, which showed it to be G-type crystal.
[0160] Method 3: The compound represented by formula (I) (21 mg) was added with Ca(OH)2 (2 mg), and 0.2 mL of EtOH / H2O (9:1, v / v) was added, followed by magnetic stirring at room temperature for 3 days, filtration, and vacuum drying at 50 °C for 2 hours to obtain G-type crystals.
[0161] Method 4: The compound represented by formula (I) (21 mg) was added with Ca(OH)2 (2 mg), and 0.2 mL of IPA / H2O (9:1, v / v) was added, followed by magnetic stirring at room temperature for 4 days, filtering, and drying in vacuum at 50 °C for 2 hours to obtain G-type crystals.
[0162] For the product filtered by Method 3, different drying times, temperatures, or vacuum levels were used to measure the water and solvent contents, and their XRPDs were detected, and the results are shown in Table 20 below.
[0163] [Table 20] [Table 21] [Table 22] [Table 23] [Table 24]
[0164] Stability of G-form crystals in different solvents:
[0165] Method 1: 0.5 mL of the corresponding solvent (corresponding solvent can be EtOH, HO, EtOH / HO=970 / 30, 927 / 73, 855 / 145, 704 / 296, v / v) was added to the G-type crystals (50 mg), magnetically stirred at room temperature for 4 days, filtered, and vacuum dried at 50°C for 2 hours to obtain the G-type crystals.
[0166] Method 2: G-type crystals (15 mg) were added to a 4 mL vial and placed in a 20 mL vial containing 3 mL of a volatile solvent (which may be MeOH or EtOH). The 20 mL vial was tightly capped and left at room temperature for about 1 week, then filtered and dried in vacuum at 50° C. for 2 hours to obtain G-type crystals.
[0167] Example 8: Preparation of H-type crystals To the G-type crystals (50 mg) was added MeOH (0.5 mL), the mixture was stirred magnetically at room temperature for 4 days, and filtered to obtain H-type crystals.
[0168] Example 9: Preparation of Form I crystals The G-type crystals (50 mg) were placed in an HPLC vial, MeOH (0.5 mL) was added, and the mixture was stirred magnetically at 50° C. for 7 days to obtain a suspension, which was then filtered to obtain the I-type crystals.
[0169] Example 10: Preparation of J-type crystals Method 1: 0.5 mL of solvent (the solvent can be 2-butanol or toluene) was added to the G-type crystals (50 mg), magnetically stirred at room temperature for 4 days, and filtered to obtain the J-type crystals. Method 2: G-type crystals (50 mg) were added to an HPLC vial, IPA (0.5 mL) was added, and the mixture was stirred magnetically at 50° C. for 7 days to obtain a suspension, which was then filtered to obtain J-type crystals. Method 3: G-type crystals (50 mg) were added to an HPLC vial, and EtOAc / n-heptane=1 / 2, v / v (0.5 mL) was added, followed by magnetic stirring at 50° C. for 7 days to obtain a suspension, which was then filtered to obtain J-type crystals. Method 4: ∼21 mg of the compound of formula (I) in Example 1 (purity 93 area %) and ∼2 mg of Ca(OH) were weighed into an HPLC vial, 0.2 mL of EtOH / HO (9:1, v / v) was added, and the mixture was magnetically stirred at room temperature for 3 days. After stirring, the mixture was centrifuged and the wet sample was detected by XRPD to be J-type crystals.
[0170] Example 11: Preparation of K-type crystals The G-type crystals (50 mg) were added to an HPLC vial, and 2-MeTHF / n-heptane=1 / 2, v / v (0.5 mL) was added thereto. The mixture was stirred magnetically at 50° C. for 7 days to obtain a suspension, which was then filtered to obtain the K-type crystals.
[0171] Example 12: Preparation of L-type crystals Under nitrogen gas protection, the K-type crystals were heated to 80° C. and cooled to room temperature to obtain L-type crystals.
[0172] Example 13: Preparation of M-type crystals The G-type crystals (15 mg) were added to a 20 mL glass bottle, DMF was added, and the mixture was stirred at room temperature to dissolve. H2O was slowly added to the glass bottle until a solid appeared, and the mixture was filtered to obtain the M-type crystals.
[0173] Example 14: Preparation of N-type crystals G-type crystals (15 mg) were added to a 4 mL glass bottle, and DMF was added to dissolve the crystals transparently. If the crystals could not be dissolved transparently, the suspension was filtered through a membrane (nylon membrane, membrane pore size 0.22 μm), and the solutions were each placed into 20 mL glass bottles containing 4 mL of HO. The 20 mL glass bottles were tightly capped, left at room temperature until solids precipitated, and then filtered to obtain N-type crystals.
[0174] Example 15: Preparation of O-type crystals The G-type crystal sample was dissolved in acetone and allowed to stand for about 10 minutes, after which a solid precipitated and was filtered to obtain the O-type crystal.
[0175] Example 16: Preparation of P-type crystals The G-type crystals (15 mg) were added to a 20 mL glass bottle, and acetone was added and stirred at room temperature to dissolve. MTBE was gradually added to the glass bottle until a solid appeared, and the crystals were filtered to obtain the P-type crystals.
[0176] Example 17: Preparation of Q-type crystals The compound represented by formula (I) (110 mg) was added to a 20 mL one-neck flask, EtOH (1 mL) was added, and the mixture was stirred magnetically until it became transparent. Sodium ethoxide (16 mg) was added, and the mixture was reacted at 40°C for 1 hour with magnetic stirring. 0.1 mL of an aqueous strontium chloride solution (300 mg / mL) was added dropwise, and the mixture was reacted at 28°C for 12 hours with stirring. The mixture was filtered and dried to obtain Q-type crystals.
[0177] Example 18 The inventors found that among the A-Q type crystals disclosed above, some have poor preparation reproducibility and some cannot be purified. Therefore, they selected four types of crystals, namely, A type crystals, B type crystals, G type crystals, and Q type crystals, which have good preparation reproducibility and are easy to purify, and performed tests under the same conditions, namely, high temperature, high humidity, and light conditions, to investigate their stability. The test protocol and results are shown in Table 25 below, and the changes in shape are shown in Table 26.
[0178] [Table 25] [Table 26]
[0179] From Tables 25 and 26 above, it can be seen that the G-type crystal has higher stability under high temperature, high humidity and light conditions compared to other crystals.
[0180] Example 19 The purities of the A-type crystals, B-type crystals, G-type crystals, and Q-type crystals of the same weight and packaging examined under storage conditions of 25° C. and 40° C. are shown in Table 27.
[0181] [Table 27]
[0182] From Table 27 above, it can be seen that the G-type crystal has higher stability when stored at 25°C and 40°C for 90 days.
Claims
1. A calcium salt of the compound of formula (I). [Formula 1]
2.
2. 2. The calcium salt of claim 1,
3. A G-type crystal of the compound represented by formula (II), characterized in that the powder X-ray diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.98±0.2°, 10.12±0.2°, 13.56±0.2°, 14.66±0.2°, 15.22±0.2°, and 18.48±0.2°.
4. The G-type crystal according to claim 3, characterized in that the powder X-ray diffraction pattern of the G-type crystal has characteristic diffraction peaks at the following 2θ angles: 8.98±0.2°, 10.12±0.2°, 13.56±0.2°, 14.66±0.2°, 15.22±0.2°, 16.34±0.2°, 16.92±0.2°, 18.48±0.2°, 22.67±0.2°, and 23.06±0.2°.
5. The G-type crystal according to claim 3 or 4, characterized in that the powder X-ray diffraction pattern of the G-type crystal is essentially the powder X-ray diffraction pattern shown in FIG.
6. Further comprising water and a solvent, however, the solvent is selected from ethanol and isopropyl alcohol; The content of the solvent is 0.1% to 6.0%; The G-type crystal according to claim 3 or 4, characterized in that the water content is 0.1% to 4.0%.
7. A method for preparing G-type crystals, comprising dissolving the compound represented by formula (I) in a sodium ethoxide solution, followed by stirring in the presence of calcium chloride, filtering and drying under reduced pressure to obtain G-type crystals.
8. A pharmaceutical composition comprising the calcium salt according to claim 1 or 2, or the G-type crystal according to any one of claims 3 to 6.
9. Use of the calcium salt according to claim 1 or 2, or the G-type crystal according to any one of claims 3 to 6, or the pharmaceutical composition according to claim 8 in the preparation of a medicine for use in treating an S1P1 receptor-related disease.
10. 10. The use according to claim 9, wherein the S1P1 receptor associated disease is selected from ulcerative colitis, Crohn's disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, primary biliary cholangitis, atopic dermatitis, intracerebral hemorrhage, graft versus host disease, psoriasis, type I diabetes, acne, microbial infections or diseases, and viral infections and diseases.
Citation Information
Patent Citations
Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative
WO2020114475A1
